<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="362721">
  <stage>Registered</stage>
  <submitdate>5/07/2012</submitdate>
  <approvaldate>6/07/2012</approvaldate>
  <actrnumber>ACTRN12612000727842</actrnumber>
  <trial_identification>
    <studytitle>Efficacy of Lithium as an Adjunctive Therapy for HIV associated neurocognitive impairment Trial</studytitle>
    <scientifictitle>Efficacy of lithium as an adjunctive therapy to antiretroviral regimens in treating HIV associated Mild Neurocognitive Disorder</scientifictitle>
    <utrn />
    <trialacronym>ELATe</trialacronym>
    <secondaryid>Nil known</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>HIV associated Mild Neurocognitive Disorder</healthcondition>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Other neurological disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Acquired immune deficiency syndrome (AIDS / HIV)</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Mental Health</conditioncode1>
      <conditioncode2>Studies of normal psychology, cognitive function and behaviour</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Lithium (oral capsules), 250 mg twice daily for 12 weeks</interventions>
    <comparator>Placebo (microcellulose capsule)</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>The primary endpoint for this trial is change in overall neurocognitive function.

1. Speed of information processing: WAIS-III Digit Symbol; Trail Making Test, Part A
2. Learning And Recall: Hopkins Verbal Learning Test-Revised
3. Abstraction/Executive functioning: Wisconsin Card Sort Test-64; Trail Making Test, Part B; Stroop Task
4. Verbal fluency: Controlled Oral Word Association Test (FAS)
5. Attention/Working memory: WMS-III-Spatial Span; PASAT
6. Motor: Grooved Pegboard Test (both hands)
7. Premorbid Functioning: National Adult Reading Test (NART)</outcome>
      <timepoint>Baseline and 12-weeks post baseline</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>As a secondary endpoint we will examine grey and white matter changes based in T1-weighted and T2-weighted imaging sequences.</outcome>
      <timepoint>Baseline and 12-weeks post baseline</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Participants must meet all of the following inclusion criteria to participate in this study:
1. HIV-positive
2. Age 18-65 years
3. Diagnosis of Asymptomatic Neurocognitive Impairment or Mild Neurocognitive Disorder
4. Karnofsky score &gt; 49
5. Stable cART for at least 12 weeks prior to study entry
6. English fluency</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>All participants meeting any of the following exclusion criteria at baseline will be excluded from study participation:
1. Current bipolar disorder, major depressive disorder, schizophrenia
2. Creatinine &gt; 110 umol/L or Urea &gt;8.0  mmol/L  (i.e. significant renal disease)
3. Clinically significant cardiovascular, renal, or thyroid disease
4. Neurologic diseases other than HIV-associated neurocognitive impairment that are known to affect cognition
5. Pregnant or nursing women
6. Untreated or unstable psychiatric illness
7. Severe pre-morbid psychiatric illness
8. Active alcohol or drug abuse
9. Active, symptomatic, opportunistic infections
10. Absolute neutrophil count &lt; 500 cells/micro litres
11. Currently taking precautionary or prohibited medications</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>1/08/2012</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>100</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>University of Melbourne</primarysponsorname>
    <primarysponsoraddress>Royal Melbourne Hospital
Department of Psychiatry
Level 1 North
Parkville, VIC 3050</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Abbott</fundingname>
      <fundingaddress>32-34 Lord Street 
BOTANY NSW 2019</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>Hospital</othercollaboratortype>
      <othercollaboratorname>Alfred Hospital</othercollaboratorname>
      <othercollaboratoraddress>Department of Infectious Diseases
Commercial Road, Melbourne, Victoria 3004</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Hospital</othercollaboratortype>
      <othercollaboratorname>St. Vincent's Hospital</othercollaboratorname>
      <othercollaboratoraddress>Department of Neurology
Level 4 Xavier Building
Victoria St Darlinghurst, Sydney, NSW 2010</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to investigate the efficacy of lithium as an adjunctive therapy to combined antiretroviral therapy in alleviating HIV associated neurocognitive impairment. We are also investigating whether lithium protects against brain changes that have also been observed in HIV associated neurocognitive impairment.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Chad Bousman</name>
      <address>Royal Melbourne Hospital
Department of Psychiatry
Level 1 North
Parkville, VIC 3050</address>
      <phone>+610390356667</phone>
      <fax />
      <email>cbousman@unimelb.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Chad Bousman</name>
      <address>Royal Melbourne Hospital
Department of Psychiatry
Level 1 North
Parkville, VIC 3050</address>
      <phone>+610390356667</phone>
      <fax />
      <email>cbousman@unimelb.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>